ClinicalTrials.gg

Program

tambotatug pelitecan

Also written as “YL201”, “YL201 for Injection” and “Tambotatug pelitecan”.

Its studies are mostly in Small Cell Lung Carcinoma · Nasopharyngeal Carcinoma · Pancreatic Neoplasms · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 3, since Sep 23, 202413 company-led studies, 13 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)1212 open or runningphase 3since Sep 23, 2024Jun 16, 2022Jan 2027phase 2 · NCT07208773
Amgen11 open or runningphase 1since Mar 21, 2025Mar 21, 2025Jun 23, 2031phase 1 · NCT06898957
  • Named in hoffmann la roche’s own pipeline as RG6919 tambotatug pelitecan (MediLink), phase 1, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche, Fosun Pharma and Akesobio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2022First study: phase 2 study in Advanced Solid TumorNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT05434234 · 312 planned · United States, Canada, China and more
  2. Sep 21, 2023Phase 2 study in Advanced Solid TumorMediLink Therapeutics (Suzhou) · NCT06057922 · 990 enrolled · China
  3. Jan 28, 2024Phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)MediLink Therapeutics (Suzhou) · NCT06241846 · 100 planned · China
  4. Apr 23, 2024Phase 1 study in Advanced Solid TumorsMediLink Therapeutics (Suzhou) · NCT06394414 · 187 enrolled · China
  5. Sep 23, 20242 phase 3 studiesMediLink Therapeutics (Suzhou) · NCT06612151, NCT06629597
  6. Mar 21, 2025Amgen’s first study: phase 1 study in Small Cell Lung CarcinomaNew to AmgenAmgen · NCT06898957 · 29 enrolled · United States, Canada, China and more
  7. Sep 28, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT07208773 · 260 planned · China
  8. Nov 17, 2025Phase 2 study in RecurrenceMediLink Therapeutics (Suzhou) · NCT07258979 · 202 planned · China
  9. Feb 6, 2026Phase 2 study in Thoracic NeoplasmsMediLink Therapeutics (Suzhou) · NCT07407933 · 118 planned · United States, Belgium, France and more
  10. Mar 17, 2026Phase 3 study in Advanced Esophageal Squamous Cell CarcinomaMediLink Therapeutics (Suzhou) · NCT07487896 · 440 planned · China
  11. Jul 28, 2026Phase 3 study in SCLC, Extensive StageMediLink Therapeutics (Suzhou) · NCT07739758 · 442 planned · China
  12. Aug 31, 2026Phase 3 study in Pancreatic NeoplasmsMediLink Therapeutics (Suzhou) · NCT07803783 · 320 planned · China

Ahead

  1. Jan 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT07208773
  2. Feb 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)MediLink Therapeutics (Suzhou) · NCT06241846
  3. Apr 6, 2027Primary completion: phase 2 study in Advanced Solid TumorMediLink Therapeutics (Suzhou) · NCT05434234
  4. Apr 29, 2027Primary completion: phase 1 study in Advanced Solid TumorsMediLink Therapeutics (Suzhou) · NCT06394414

TargetBeta

“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic ac…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07803783Pancreatic Neoplasms · China3Not yet recruitingMediLink Therapeutics (Suzhou)Jan 2029320
NCT07739758SCLC, Extensive Stage · China3RecruitingMediLink Therapeutics (Suzhou)Jun 2029442
NCT07487896Advanced Esophageal Squamous Cell Carcinoma · China3RecruitingMediLink Therapeutics (Suzhou)Apr 30, 2028440
NCT07407933Thoracic Neoplasms · United States, Belgium, France and more2RecruitingMediLink Therapeutics (Suzhou)Nov 2028118
NCT07258979Recurrence · China2RecruitingMediLink Therapeutics (Suzhou)Feb 2028202
NCT07208773Carcinoma, Non-Small-Cell Lung · China2RecruitingMediLink Therapeutics (Suzhou)Jan 2027260
NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more1Active, not recruitingAmgenJun 23, 203129
NCT06629597Nasopharyngeal Carcinoma · China3Active, not recruitingMediLink Therapeutics (Suzhou)Dec 1, 2027400
NCT06612151Small Cell Lung Carcinoma · China3Active, not recruitingMediLink Therapeutics (Suzhou)Dec 1, 2027438
NCT06394414Advanced Solid Tumors · China1Active, not recruitingMediLink Therapeutics (Suzhou)Apr 29, 2027187
NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC) · China2RecruitingMediLink Therapeutics (Suzhou)Feb 2027100
NCT06057922Advanced Solid Tumor · China2Active, not recruitingMediLink Therapeutics (Suzhou)Oct 2026990
NCT05434234Advanced Solid Tumor · United States, Canada, China and more2RecruitingMediLink Therapeutics (Suzhou)Apr 6, 2027312

How it is read

Names in the registry

  • “YL201”, 11 entries
  • “YL201 for Injection”, 2 entries
  • “Tambotatug pelitecan”, 1 entry
  • “YL201 and atezolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.